Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CASP6 | P55212 | 1/20 | 0.38 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1370309 | 0.85 | VCAM1 (0.36) | ALDH1A1MEN1KMT2APOLBMAPT | |
| SCHEMBL1369312 | 0.85 | ALDH1A1 (0.44) | SMN1; SMN2ALDH1A1LMNAGAAHTT | |
| SCHEMBL1367697 | 0.81 | MEN1 (0.45) | SMN1; SMN2ALDH1A1LMNAGAAHTT | |
| SCHEMBL1369070 | 0.81 | ALDH1A1 (0.41) | SMN1; SMN2ALDH1A1LMNAGAAHTT | |
| SCHEMBL1366877 | 0.81 | SMN1; SMN2 (0.45) | SMN1; SMN2ALDH1A1LMNAHTTMEN1 | |
| SCHEMBL1366812 | 0.80 | ALDH1A1 (0.47) | SMN1; SMN2ALDH1A1LMNAGAAHTT | |
| SCHEMBL1368727 | 0.80 | ALDH1A1 (0.43) | SMN1; SMN2ALDH1A1LMNAGAAHTT | |
| SCHEMBL829796 | 0.79 | SMN1; SMN2 (0.40) | SMN1; SMN2ALDH1A1LMNAGAAHTT | |
| SCHEMBL1368421 | 0.79 | ALDH1A1 (0.42) | SMN1; SMN2ALDH1A1LMNAGAAHTT | |
| SCHEMBL1367352 | 0.75 | PIK3CA (0.41) | SMN1; SMN2LMNAGAAHTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275650-A1 | 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof | TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-11-05 | — | — | US | claimed |
| WO-2006132947-A2 | 3-ACYL COUMARINS, THIOCHROMONES AND QUINOLONES AND THERAPEUTIC USES THEREOF | TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-12-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275650-A1 | 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof | NQO2, NQO1, HCCS | SMN1; SMN2 4848/4885ALDH1A1 617/4885LMNA 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.